A Single-Arm, Phase 1b Study to Assess Tumor-Treating Fields (TTF) in Combination With Durvalumab and Gemcitabine/Cisplatin (GemCis) as the First-Line Treatment of Unresectable Biliary Tract Cancers (BTC)
Latest Information Update: 29 Oct 2024
At a glance
- Drugs Cisplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 26 Oct 2024 Status changed from not yet recruiting to recruiting.
- 03 Oct 2024 New trial record